MedTrace Logo

Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes

NCT07145502 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2025-09-05

No results posted yet for this study

Summary

This is a prospective, non-randomized, observational registry study evaluating the clinical outcomes of patients with autoimmune or post-infectious neuroinflammatory syndromes receiving stem cell-derived biologics (including mesenchymal stem cells and exosomes) at Biocells Medical clinics. The study aims to track improvements in neurological function, inflammatory biomarkers, and patient-reported quality of life following individualized regenerative interventions.

Conditions

  • Autoimmune Encephalitis
  • Early-stage Panencephalitis
  • Neuroinflammatory Demyelination

Interventions

BIOLOGICAL

Allogeneic MSC infusions (IV)

Optional T-reg therapy (experimental/compassionate-use basis)

Sponsors & Collaborators

  • Biocells Medical

    lead INDUSTRY

Eligibility

Min Age
6 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-19
Primary Completion
2024-07-15
Completion
2027-09-19
FDA Drug
Yes

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07145502 on ClinicalTrials.gov